Q3 2026 Ashland Inc Earnings Call Transcript
Key Points
- Ashland Inc (ASH) delivered a strong third quarter with a 7% year-over-year sales increase, driven by volume growth across all business units.
- Life Sciences achieved double-digit sales growth, marking its fifth consecutive quarter of volume gains, supported by strong demand in pharma applications.
- Personal Care reported solid performance with high single-digit growth in skincare and favorable contributions from hair care and microbial protection.
- Specialty Additives experienced sales growth due to market share gains and strong commercial execution in coatings and performance specialties.
- Ashland Inc (ASH) generated strong cash flow during the quarter, ending with a net leverage of 2.4x, aligning with its long-term target range.
- Profitability was impacted by production challenges earlier in the fiscal year, with adjusted EBITDA decreasing to $109 million from $113 million in the prior year quarter.
- Adjusted EBITDA margin declined to 21.9% from 24.4% in the prior year quarter, reflecting lower production rates and cost pressures.
- Intermediates segment saw a decline in adjusted EBITDA due to lower advanced manufacturing tax credits compared to the prior year.
- Specialty Additives faced continued weakness in construction and energy markets, impacting overall performance.
- The company revised its adjusted EPS outlook to low to mid-single-digit growth from mid to high single-digit growth due to a higher tax rate associated with unfavorable discrete items.
Good day, and thank you for standing by. Welcome to the Ashland third quarter conference earnings call. (Operator Instructions) Please be advised that today's conference call is being recorded.
I would now like to hand the conference over to your first speaker today, Sandy Klugman, Director of Investor Relations. Thank you, Sandy.
Thank you. Hello, everyone, and welcome to Ashland's third quarter fiscal year 2026 earnings conference call and webcast. My name is Sandy Klugman, and I am Ashland's Director of Investor Relations.
Joining me on the call today are Guillermo Novo, Chair and CEO; William Whitaker, CFO; as well as our business unit leaders, Alessandra Assis, Life Sciences and Intermediates; Jim Minicucci, Personal Care; and Dago Caceres, Specialty Additives.
Please note that we will be referencing slides during today's call. We encourage you to follow along with webcast and materials available at ashland.com under Investor Relations.
Please
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
Trustpilot
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
